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DObjective: To determine the contemporary outcomes of surgical aortic valve replacement (SAVR) in a moderate
surgical risk population.
Methods: We studied 502 consecutive adults who had undergone isolated SAVR from January 2002 to June
2011 for severe aortic valve stenosis with a Society of Thoracic Surgery predicted risk of mortality of 4% to
8%. We included concomitant coronary artery bypass and aortic annular enlargement but not other concomitant
procedures. The updated Valve Academic Research Consortium definitions were used, as appropriate.
Results: Themedian agewas 80 years (range, 49-96), 323 (64.3%) had NewYork Heart Association class III-IV
symptoms, and 101 (20.1%) had undergone previous coronary artery bypass grafting. The mean predicted risk
of mortality was 5.6%. Concomitant coronary artery bypass grafting was performed in 270 (53.8%).
Re-exploration for bleeding occurred in 29 (5.8%), stroke in 9 (1.8%), and vascular complications in
2 (0.4%). In the cohort, 14 early deaths (2.8%) occurred. During follow-up (1174 days), 175 patients died.
Using multivariate logistic regression analysis, the significant independent predictors of mid-term death
included chronic pulmonary disease (hazard ratio, 2.00, 95% confidence interval, 1.41-2.84; P < .001),
peripheral vascular disease (hazard ratio, 1.58; 95% confidence interval, 1.05-2.37; P ¼ .029), and atrial
fibrillation (hazard ratio, 1.75; 95% confidence interval, 1.16-2.65; P ¼ .008).
Conclusions: SAVR in moderate-risk patients is currently performed with one half of the early predicted risk
(2.8%) and a low likelihood of complications, including a 1.8% incidence of stroke. Patients counseled for
randomization to transcatheter aortic valve insertion should be informed of the excellent early to mid-term
outcomes of SAVR, particularly those without pulmonary impairment, peripheral vascular disease, or atrial
fibrillation. (J Thorac Cardiovasc Surg 2014;147:127-32)Senile calcific aortic valve stenosis is the most frequent
heart valve condition of elderly patients and has been
associated with an excess mortality once symptoms
appear.1-3 Surgical aortic valve replacement (SAVR) has
been proved to improve symptoms and prolong survival,
with very low morbidity and mortality.4 Recent randomized
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The Journal of Thoracic and Cavalve implantation (TAVR) offers similar rates of survival
and symptom improvement to high-risk and inoperable
patients at 2 years of follow-up.5 When considering therapy
for patients with aortic stenosis (AS) at lower surgical risk,
genuine uncertainty exists regarding the best treatment
option, particularly for those at moderate risk of death after
SAVR (Society of Thoracic Surgeons [STS] predicted risk
of mortality [PROM], 4-8%). Three randomized controlled
trials are currently underway to ascertain the differences in
outcomes after SAVR versus TAVR in moderate-risk
patients: the Placement of Aortic Transcatheter Valve
(PARTNER) IIA trial, studying the Edwards SAPIEN XT
valve (Edwards Lifesciences, Irvine, Calif); Surgical
Replacement and Transcatheter Aortic Valve Implantation
(SURTAVI), using the Medtronic CoreValve System
(Medtronic, Minneapolis, Minn); and the St Jude Portico
trial (St Jude Medical, St Paul, Minn). The accurate
prediction of perioperative morbidity and mortality in pa-
tients referred for TAVR evaluation remains challenging,
however, because no risk model has been validated speci-
fically for TAVR candidates and the currently used surgical
scoring systems can either over- or underestimate the actual
periprocedural risk.6rdiovascular Surgery c Volume 147, Number 1 127
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
CABG ¼ coronary artery bypass grafting
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
PROM ¼ predicted risk of mortality
SAVR ¼ surgical aortic valve replacement
STS ¼ Society of Thoracic Surgeons
TAVR ¼ transcatheter aortic valve
implantation
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DWe thus sought to test the hypothesis that the STS PROM
would be capable of accurately predicting actual mortality
in moderate-risk subgroups to help inform patients’ deci-
sions and better prepare cardiac care specialists to ascertain
whether equipoise exists in the randomization of patients to
TAVR or SAVR in current trials.METHODS
Study Design and Population
The Mayo Clinic investigational review board approved the present
study. Informed consent was waived according to the investigational
review board specifications. From January 2002 to June 2011, 4499
SAVR procedures were performed at the Mayo Clinic (Rochester, Minn)
to treat aortic valve stenosis. We included those with severe aortic valve
stenosis (mean gradient  40 mm Hg) and an STS PROM of 4% to 8%
(current version data set, 2.73 of the STS risk calculator). The records
were excluded if they included multiple valve procedures or other major
nonvalve-related operations, other than coronary artery bypass grafting
(CABG) and aortic annular enlargement.
Clinical Data
The Division of Cardiovascular Surgery database, patient medical
records, follow-up questionnaires, and Social Security Death Index were re-
viewed for patient demographics, medical history, baseline symptoms,
cardiac status, perioperative complications, readmission, and early and
mid-termmortality. Thevariables evaluated during the study period included
gender, age, left ventricular ejection fraction, STS PROM, bodymass index,
diabetes mellitus, hypertension, chronic lung disease, peripheral vascular
disease, cerebrovascular disease, renal failure, atrial fibrillation, mitral
regurgitation, coronary artery disease, previousCABG, previous pacemaker,
previous percutaneous coronary intervention, previous aortic valve balloon-
plasty, previous myocardial infarction, aortic valve gradient, New York
Heart Association heart failure functional class, aortic annular enlargement,
associatedCABG, and urgent surgery. Data on thesevariableswere collected
in keeping with the standard definitions set forth by the STS as a part of the
NationalAdultCardiac SurgeryDatabase.We used the clinical endpoint def-
initions recommended by the updated Valve Academic Research Con-
sortium.7 We performed clinical follow-up examinations and sent surveys
to all patients at regular intervals of 1, 3, and 5 years after surgery to ascertain
their clinical status and postoperative complications.
Statistical Analysis
Continuous data are expressed as the mean  standard deviation or
median and range. The determined values were compared with the early
and mid-term mortality. Variables significant on univariate analysis128 The Journal of Thoracic and Cardiovascular Surgwere used during stepwise selection to create the final multivariate model.
Statistical significance was considered at P<.05. Early operative mortality
was defined as death occurring within 30 days of surgery or at any point
during the index hospitalization.RESULTS
A total of 502 patients who met the inclusion criteria
were included in the present analysis. The baseline
characteristics of the patients are listed in Table 1. The
median patient age was 80 years (range, 49-96), and 277 pa-
tients (55.2%) were men. The mean STS PROM was 5.6%
(standard deviation  1.09). Hypertension was present in
415 patients (82.7%), diabetes mellitus in 157 (31.3%),
chronic pulmonary disease in 119 (23.7%), and renal
failure, defined as a basal creatinine  2.0 mg/dL, in 20
(4.0%). Only 2 patients (0.4%) were dialysis dependent
preoperatively. Atrial fibrillation was present in 45 patients
(9.0%), previous myocardial infarction in 43 (8.6%), previ-
ous percutaneous coronary intervention in 79 (15.7%), and
previous percutaneous aortic balloon-plasty in 2 (0.4%). Of
the 502 patients, 323 (64.3%) presented with New York
Heart Association class III-IV heart failure symptoms.
The mean left ventricular ejection fraction was 60%. Previ-
ous CABG had been performed in 101 patients (20.1%).
Urgent surgery was required in 64 patients (12.7%). The
median crossclamp and cardiopulmonary bypass time was
60 and 82 minutes, respectively. Aortic valve bioprostheses
were implanted in 477 patients (95.0%). Concomitant
CABG was necessary in 270 patients (53.8%). Aortic
annular enlargement with a pericardial patch was necessary
in 25 patients (5.0%). Red blood cell transfusion was
required in 296 patients (59.0%). The median mechanical
ventilation and intensive care unit admission duration was
13.5 hours (range, 3-1092) and 28 hours (range, 5-849),
respectively.
The frequencies of early complications are listed in
Table 2. These included re-exploration for bleeding in 29
(5.8%), atrial fibrillation or flutter in 207 (41.2%), peri-
operative myocardial infarction in 2 (0.4%), stroke in 9
(1.8%), acute kidney injury stage II in 23 (4.6%),
new-onset dialysis in 11 (2.1%), pneumonia in 20
(4.0%), major vascular complications in 2 (0.4%; lower
extremity ischemia secondary to the use of a femoral
intra-aortic balloon pump), and deep sternal infection in 1
patient (0.2%).
There were 14 (2.8%) early deaths, of which 9 (64.3%)
were cardiac related. Three were immediate procedural
mortalities according to the updated Valve Academic
Research Consortium criteria. Of the 232 patients who
had undergone isolated aortic valve replacement, 6
(2.58%) died compared with 8 of 270 (2.96%) who
undergone associated CABG (P ¼ .798). We were unable
to identify univariate predictors of early death, including
previous CABG, concomitant CABG, and STS PROMery c January 2014
TABLE 1. Baseline characteristics (n ¼ 502)
Characteristic Value
Median age (y) 80 (49-96)
Male gender 277 (55.2)
Mean STS PROM (%) 5.6 (SD  1.09)
Mean body mass index (kg/m2) 28 (SD  6.05)
NYHA class
I or II 179 (35.7)
III or IV 323 (64.3)
Type 2 diabetes mellitus
Total 157 (31.3)
Insulin dependent 53 (10.6)
Hypertension 415 (82.7)
Cerebral vascular disease 125 (24.9)
Peripheral vascular disease 77 (15.3)
Chronic lung disease
Mild 70 (14.0)
Moderate 14 (2.8)
Severe 35 (7.0)
Creatinine level  2.0 mg/dL 20 (4.0)
Mean aortic valve gradient (mm Hg) 51 (40-112)
Aortic regurgitation
Trivial or mild 325 (64.7)
Moderate 72 (14.3)
Severe 5 (1)
Mitral regurgitation
Trivial or mild 381 (75.9)
Moderate 83 (16.5)
Severe 2 (0.4)
Median LVEF (%) 63 (13-84)
Atrial fibrillation 45 (9.0)
Coronary artery disease 399 (79.5)
Permanent pacemaker 26 (5.2)
Previous CABG 101 (20.1)
Previous myocardial infarction 43 (8.6)
Previous coronary percutaneous intervention 79 (15.7)
Previous percutaneous aortic balloon-plasty 2 (0.4)
Data presented as mean (range) or n (%). STS PROM, Society of Thoracic Surgeons
predicted risk of mortality; SD, standard deviation; NYHA, New York Heart Associ-
ation; LVEF, left ventricular ejection fraction; CABG, coronary artery bypass
grafting.
TABLE 2. Early postoperative complications (n ¼ 502 patients)
Complication n (%)
Transfusion of red blood cells 296 (59.0)
2 U 228 (45.4)
Atrial fibrillation or flutter 207 (41.2)
Reoperation for bleeding 29 (5.8)
Pneumonia 20 (4.0)
Acute kidney injury, stage II 23 (4.6)
Dialysis 11 (2.2)
Permanent pacemaker 10 (1.9)
Stroke 9 (1.8)
Perioperative myocardial infarction 2 (0.4)
Major vascular complications 2 (0.4)
Deep sternal infection 1 (0.2)
Endocarditis 0
TABLE 3. Univariate logistic regression models predicting early
death
Variable OR (95% CI) P value
Gender 2.27 (0.75-6.86) .148
Age 1.01 (0.94-1.09) .79
LVEF 1.01 (0.96-1.06) .689
STS PROM 1.07 (0.66-1.73) .774
Body mass index 0.93 (0.83-1.03) .147
Diabetes 0.59 (0.16-2.15) .425
Hypertension 0.76 (0.21-2.79) .682
Chronic pulmonary disease 1.89 (0.42-8.85) .408
Peripheral vascular disease 1.53 (0.42-5.6) .524
Cerebral vascular disease 1.7 (0.56-5.18) .348
Renal failure 0 NA
Atrial fibrillation 0 NA
Mitral regurgitation 1.36 (0.37-5.04) .648
Previous pacemaker 0.7 (0.09-5.58) .738
Previous percutaneous coronary intervention 2.03 (0.6-6.93) .257
Previous CABG 0.3 (0.04-2.31) .247
Previous myocardial infarction 1.92 (0.59-6.28) .278
Aortic gradient 0.99 (0.94-1.04) .651
Chronic heart failure 1.19 (0.33-4.35) .793
Annular enlargement 3.1 (0.64-15.01) .159
Associated CABG 1.15 (0.39-3.36) .798
Urgent surgery 0.52 (0.07-4.04) .531
OR, Odds ratio; CI, confidence interval; LVEF, left ventricular ejection fraction;
STS PROM, Society of Thoracic Surgeons predicted risk of mortality; NA, not appli-
cable; CABG, coronary artery bypass grafting.
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plus stroke and renal failure and reoperation secondary to
bleeding, and found no significant association with any of
the previous variables analyzed (Table 3).
The median postoperative length of stay was 7 days
(range, 3-70). Discharge to home was obtained for 328
(65.3%), and the remaining patients required some type
of assistance (extended care or a nursing home). Finally,
41 patients (8.2%) required readmission within 30 days
of surgery.
During the mid-term follow-up period of 1174 days, 175
patients died (out of hospital and>30 days after surgery).
Overall survival at 2, 4, and 6 years was 87.86% (range,
84.79%-91.04%), 74.75% (range, 70.46%-79.29%), and
59.15% (range, 53.57%-65.32%), respectively.The Journal of Thoracic and CaOn multivariate logistic regression analysis, the signi-
ficant predictors of mid-term death included chronic pulmo-
nary disease (hazard ratio, 2.00; 95% confidence interval,
1.41-2.84; P<.001), peripheral vascular disease (hazard ra-
tio, 1.58; 95% confidence interval, 1.05-2.37; P ¼ .029),
and atrial fibrillation (hazard ratio, 1.75; 95% confidence
interval, 1.16-2.65; P ¼ .008; Table 4). Compared with an
age- and gender-matched general population group without
AS, no statistically significant difference was found in late
survival was identified (Figure 1).rdiovascular Surgery c Volume 147, Number 1 129
TABLE 4. Cox regression model predicting mid-term mortality
Variable
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value>chi-square
Chronic pulmonary disease 1.74 (1.27-2.39) <.001 2.00 (1.41-2.84) <.001
Peripheral vascular disease 1.62 (1.11-2.37) .013 1.58 (1.05-2.37) .029
Atrial fibrillation 1.67 (1.11-2.53) .014 1.75 (1.16-2.65) .008
HR, Hazard ratio; CI, confidence interval; Pr, probability.
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DDISCUSSION
In those with severe aortic valve stenosis who are
at very high risk of SAVR or are considered surgically
‘‘inoperable,’’ randomized prospective trials and observa-
tional series have reported improved survival after TAVR
compared with medical therapy.8 Furthermore, TAVR has
been shown to be as safe and effective as SAVR in those
with high surgical risk.5 Despite the rapid expansion of
information addressing these 2 subsets, however, a paucity
of data is available specifically examining those at interme-
diate risk for SAVR with an STS PROM of 4% to 8%
currently being considered for randomization in the
PARTNER II, SURTAVI, and PORTICO studies world-
wide. We thus sought to determine the contemporary
outcomes of SAVR, adhering to criteria used in determining
the candidacy for the PARTNER IIA trial to assist clinicians
in ascertaining and conveying the results of SAVR to
patients in the current era.9 We found that SAVR with or
without combined CABG can be performed with approxi-
mately one half the early mortality predicted by the current
version (data set 2.73) of the STS risk calculator. Surgical
excision of the senescent native aortic valve, followed
prosthetic valve replacement carried a very low risk of
complications, including a 1.8% incidence of stroke and
<1% risk of major vascular complications.
Debate has been ongoing regarding themost accurate risk
determination algorithm to assist cardiac care professionals
with stratification of patients into various treatment
modalities.10,11 Previous studies have demonstrated that
the assessment of periprocedural risk using a risk
calculator alone might not be completely reliable, with a
tendency toward an overestimation of liability in higher
risk patients. A previous report from our group concluded
that the European System for Cardiac Operative Risk
Evaluation (EuroSCORE) should not be used to determine
operability for isolated SAVR owing to its tendency to
overestimate mortality in the low-, intermediate-, and
high-risk subgroups.12 Although the STS PROM is
currently the most widely used system, it predicted nearly
double the observed mortality in our present analysis.
Current models could be improved by the addition of
specific clinical and anatomic variables that affect mortal-
ity. For example, the presence of a porcelain aorta and
frailty are important factors not included in either risk130 The Journal of Thoracic and Cardiovascular Surgmodel but routinely considered during patient evaluation.
Similar attempts to compare actual SAVR and TAVR
mortality using the EuroSCORE and STS PROM in a
high-risk population13 also showed better surgical results
than that predicted using the currently available preopera-
tive risk stratification models.
Four studies have been published comparing TAVR and
SAVR in moderate- and/or low-risk patients.14-17 A
nonrandomized study by Wenaweser and colleagues14
described the use of TAVR in low-risk (STS score,<3%),
intermediate-risk (STS score, 3%-8%), and high-risk
(STS score,>8%) patients, with all-cause mortality at 30
days of 2.4%, 3.9%, and 14.9% (P<.001) and at 1 year
of 10.1%, 16.1%, and 34.5% (P< .0003), respectively.
They concluded that candidacy for TAVR should not be
guided by fulfillment of absolute risk score criteria but by
the opinion of an interdisciplinary heart team after the
clinical evaluation. The Italian Observational Study of
Appropriateness, Efficacy, and Effectiveness of AVR-
TAVI Procedures for the Treatment of Severe Symptomatic
Aortic Stenosis (OBSERVANT) research group studied a
low- to moderate-risk matched population undergoing
aortic valve replacement (mean logistic EuroSCORE,
9.4%  10.4% for SAVR and 8.9%  9.5% for TAVR).
They reported a 30-day mortality of 3.8% for both groups.
In their study, SAVR was associated with a greater risk of
blood transfusion, and TAVR resulted in a significantly
increased rate of vascular injury, permanent atrioventricular
block, and residual aortic valve regurgitation.15 Another
Italian study by Latib and colleagues16 identified 182
consecutive patients who had undergone TAVR, comparing
them against 111 moderate- to high-risk historical SAVR
case controls. Using propensity score matching groups,
TAVR was associated with more frequent vascular compli-
cations (33.3% vs 0.9%, P<.001), and acute kidney injury
was more frequent after SAVR (8.1% vs 26.1%, P<.001).
The rate of all-cause mortality in both groups was 1.8% at
30 days (P ¼ 1.00) and 6.4% and 8.1%, respectively, at 1
year (P ¼ .80). The incidence of cerebrovascular events
was similar in the 2 groups (4.6% vs 9.1%, P ¼ .19) at 1
year.16 The Danish Prospective Randomized Trial of Trans-
apical Transcatheter Aortic Valve Implantation Versus Sur-
gical Aortic Valve Replacement in Operable Elderly
Patients With Aortic Stenosis (STACCATO) trialery c January 2014
FIGURE 1. Kaplan-Meier late survival curve compared with survival of
expected age- and gender-matched US population.
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groups. However, the Data SafetyMonitoring Board prema-
turely terminated the study after the enrollment of 70 pa-
tients because of adverse events: 2 deaths, 2 strokes, 1
case of renal failure requiring dialysis in the TAVR group
and 1 stroke in the SAVR group (P ¼ .07). In the TAVR
group, 1 patient required conversion to SAVR because of
an abnormally positioned heart and 4 patients underwent
reoperation with open heart surgery because of annulus
rupture in 1, severe paravalvular leakage in 2, and blockage
of the left coronary artery in 1.17
A large contemporary Italian study sought to determine
the risk factors for mortality during SAVR and found that
advanced heart failure, severe pulmonary hypertension,
severe chronic obstructive pulmonary disease, and central
neurologic dysfunction were independent predictors of
early mortality.18 During mid-term follow-up, a low ejec-
tion fraction and advanced age were adverse prognostic
factors.18 We did not discover any specific significant
predictors of mortality in the early postoperative period in
our present study. We did identify significant independent
predictors of death, including chronic pulmonary disease,
peripheral vascular disease, and atrial fibrillation. Our
group has previously described the adverse effect of chronic
obstructive lung disease as an independent risk factor for
long-term mortality after SAVR.19
Another important finding to highlight is that SAVR was
capable of restoring survival to that expected for an age- and
gender-matched US population sample, demonstrating
the important benefit of SAVR in the treatment of
moderate-risk patients with severe aortic valve stenosis.
Finally, we acknowledge that the surgical outcomes from
different hospitals could vary and that this could have been a
limitation of the present study. This bias could be attributed
to the complexity of the cases and the volume of SAVR in
each respective center. Thus, we believe the heart team
approach is vital to be able to determine the local data toThe Journal of Thoracic and Cagive the best treatment option to patients with AS in a
moderate-risk population in the current transcatheter era.Study Limitations
We acknowledge that the surgical outcomes will vary
between sites nationally and internationally. Despite this,
our outcomes were likely similar to those of other trans-
catheter investigational sites currently participating in the
Edwards PARTNER II, Medtronic SURTAVI, and St Jude
Portico trials. The ultimate decisions regarding the patient
treatment strategy should be made on a center-by-center
basis according to the center- and team-based clinical
experience and outcomes.CONCLUSIONS
SAVR with or without combined CABG for severe AS in
moderate-risk patients can be performed with approxi-
mately one half the early mortality predicted by the
currently used risk models in North America. Surgical
aortic valve excision with prosthetic replacement has a
very low risk of complications, including a 1.8% incidence
of stroke and<1% likelihood of vascular complications.
Patients being counseled for potential randomization to
TAVR should be informed of the excellent early to
mid-term outcomes of SAVR for those without pulmonary
disease or advanced heart failure symptoms.References
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Dr Kenton J. Zehr (Temple, Tex). To the AATS Program Com-
mittee, moderators, and the Mayo Clinic group:
Thank you for the opportunity to discuss this report and the priv-
ilege of reviewing the full study before the meeting.
Dr Iturra and the Mayo Clinic group have presented a unique
group of primarily elderly intermediate-risk group patients under-
going aortic valve replacement (AVR) or AVR plus CABG during
the recent decade. Despite an STS risk score of 4% to 8%, they
observed mortality of 2.8%. One remembers back to a report
from the same institution presented by Drs Dwight McGoon and
Emerson Moffit for the first 100 consecutive AVRs with a Starr-
Edwards valvewithout a single mortality. Good therapies find their
way. This is another report attesting to the safety and efficacy of
SAVR.
This study raises the question of the presumed equipoise to
TAVR in this group of intermediate-risk patients, and I would
rhetorically ask: ‘‘where is the evidence for equipoise?’’ You132 The Journal of Thoracic and Cardiovascular Surghave seen the low rates of complications in this presented series,
with a postoperative length of stay of 7 days and an 8.2% read-
mission rate at 30 days. Most of us can agree that the PARTNER
trial strongly confirmed the benefits of TAVR in inoperable pa-
tients and suggested equipoise for high-risk surgical patients,
but it came at a significant price. If one reviews the briefing
for the Food and Drug Administration regarding the experience
with the SAPIEN valve in the nonoperative cohort, there were
8 device malfunctions, 4 patients required an additional valve,
and 7 patients never received a valve because of access issues
and were excluded from the study. In the high-risk cohort study
in the PARTNER trial, 4 intraprocedural deaths occurred, 3 in the
TAVR group and 1 in the AVR group. Also, in 16 patients, the
procedure was aborted or converted to AVR because of intrapro-
cedural findings, 7 patients required >1 valve (2 because of
embolization and 5 because of paravalvular leak), and 5 addi-
tional valve embolizations occurred. Cardiac mortality was the
same in both groups, but the stroke rate was double. In the
Danish STACCATO trial, the study was terminated.
DrWoo. Could we ask you to ask the questions, we are short on
time.
Dr Zehr. I have just 1 question.
I want to present a little bit of our recent data. We started using
TAVR, and we have treated 34 patients within 8 months. We have
had no intraprocedural deaths, but we have had 3 deaths within 30
days. They also come at a price: a few minor vascular complica-
tions, 1 stroke, and 2 patients who required median sternotomy
for tamponade. So, we recognize the value of TAVR, but we
believe it is a real operation with real complications and in no
way have we concluded that current equipoise exists for interme-
diate-risk patients.
So, I have 1 question. How is your group addressing the pressure
to perform TAVR in these intermediate-risk patients in lieu of your
results and the current recommendations from the Food and Drug
Administration and Centers for Medicare & Medicaid Services?
Thank you very much.
Dr Iturra. Thank you for your comments and question.
The clinical records and imaging studies of each patient being
considered for either Food and Drug Administration transcatheter
trials or commercially available TAVR devices are discussed by a
multidisciplinary heart team at the Mayo Clinic. When a patient is
being considered for randomization, we use the currently available
data and solicit the opinions of all heart team members to arrive at
a determination of whether equipoise exists. If so, we provide full
disclosure of the indications, risks, benefits, and alternatives of
SAVR versus transcatheter valve therapy to each patient to allow
them to make an informed decision.ery c January 2014
